Niels HÃ, iby

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3040574/publications.pdf

Version: 2024-02-01

		38660	20307
179	14,750	50	116
papers	citations	h-index	g-index
182	182	182	14017
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Potential Advances of Adjunctive Hyperbaric Oxygen Therapy in Infective Endocarditis. Frontiers in Cellular and Infection Microbiology, 2022, 12, 805964.	1.8	7
2	Tolerance and resistance of microbial biofilms. Nature Reviews Microbiology, 2022, 20, 621-635.	13.6	316
3	Combination and nanotechnology based pharmaceutical strategies for combating respiratory bacterial biofilm infections. International Journal of Pharmaceutics, 2022, 616, 121507.	2.6	10
4	Lactoferricin-inspired peptide AMC-109 augments the effect of ciprofloxacin against Pseudomonas aeruginosa biofilm in chronic murine wounds. Journal of Global Antimicrobial Resistance, 2022, 29, 185-193.	0.9	3
5	Murine burn lesion model for studying acute and chronic wound infections. Apmis, 2022, 130, 477-490.	0.9	1
6	Dynamics of a <i>Staphylococcus aureus</i> infective endocarditis simulation model. Apmis, 2022, 130, 515-523.	0.9	6
7	Adaptive Immune Response to Mycobacterium abscessus Complex (MABSC) in Cystic Fibrosis and the Implications of Cross-Reactivity. Frontiers in Cellular and Infection Microbiology, 2022, 12, 858398.	1.8	0
8	Autologous fibrin sealant co-delivered with antibiotics is a robust method for topical antibiotic treatment after sinus surgery. Acta Oto-Laryngologica, 2021, 141, 181-186.	0.3	5
9	Pandemics: past, present, future. Apmis, 2021, 129, 352-371.	0.9	25
10	Azithromycin potentiates avian IgY effect against Pseudomonas aeruginosa in a murine pulmonary infection model. International Journal of Antimicrobial Agents, 2021, 57, 106213.	1.1	9
11	Adjunctive S100A8/A9 Immunomodulation Hinders Ciprofloxacin Resistance in Pseudomonas aeruginosa in a Murine Biofilm Wound Model. Frontiers in Cellular and Infection Microbiology, 2021, 11, 652012.	1.8	4
12	SARS-CoV-2 infection dynamics in Denmark, February through October 2020: Nature of the past epidemic and how it may develop in the future. PLoS ONE, 2021, 16, e0249733.	1.1	3
13	Maintaining normal lung function in children with cystic fibrosis is possible with aggressive treatment regardless of <i>Pseudomonas aeruginosa</i> infections. Acta Paediatrica, International Journal of Paediatrics, 2021, 110, 2607-2609.	0.7	3
14	Distinct contribution of hyperbaric oxygen therapy to human neutrophil function and antibiotic efficacy against <i>Staphylococcus aureus</i> . Apmis, 2021, 129, 566-573.	0.9	5
15	Animal models of chronic and recurrent Pseudomonas aeruginosa lung infection – significance of macrolide treatment Apmis, 2021, , .	0.9	5
16	Anti-biofilm Approach in Infective Endocarditis Exposes New Treatment Strategies for Improved Outcome. Frontiers in Cell and Developmental Biology, 2021, 9, 643335.	1.8	32
17	Microbiological findings in emergency department patients with sepsis identified by the Sepsis-3 criteria: a single-center prospective population-based cohort study. International Journal of Emergency Medicine, 2021, 14, 39.	0.6	2
18	Novel human <i>inÂvitro</i> vegetation simulation model for infective endocarditis. Apmis, 2021, 129, 653-662.	0.9	9

#	Article	IF	Citations
19	Synergistic effect of immunomodulatory S100A8/A9 and ciprofloxacin against Pseudomonas aeruginosa biofilm in a murine chronic wound model. Pathogens and Disease, 2020, 78, .	0.8	7
20	Primary ciliary dyskinesia patients have the same <i>P. aeruginosa</i> clone in sinuses and lungs. European Respiratory Journal, 2020, 55, 1901472.	3.1	7
21	Further Commentary. Pediatric Pulmonology, 2020, 55, 23-23.	1.0	0
22	The evolutionary trajectories of P. aeruginosa in biofilm and planktonic growth modes exposed to ciprofloxacin: beyond selection of antibiotic resistance. Npj Biofilms and Microbiomes, 2020, 6, 28.	2.9	29
23	Early ILâ€2 treatment of mice with Pseudomonas aeruginosa pneumonia induced PMNâ€dominating response and reduced lung pathology. Apmis, 2020, 128, 647-653.	0.9	2
24	Lymphocyte responses to Mycobacterium tuberculosis and Mycobacterium bovis are similar between BCG-vaccinated patients with cystic fibrosis and healthy controls. Journal of Cystic Fibrosis, 2020, 19, 575-579.	0.3	1
25	In vivo demonstration of Pseudomonas aeruginosa biofilms as independent pharmacological microcompartments. Journal of Cystic Fibrosis, 2020, 19, 996-1003.	0.3	15
26	Pseudomonas aeruginosa antibody response in cystic fibrosis decreases rapidly following lung transplantation. Journal of Cystic Fibrosis, 2020, 19, 587-594.	0.3	5
27	Antibody response against Pseudomonas aeruginosa and its relationship with immune mediators in the upper and lower airways of cystic fibrosis patients. Pediatric Pulmonology, 2020, 55, 959-967.	1.0	3
28	Biofilms of Mycobacterium abscessus Complex Can Be Sensitized to Antibiotics by Disaggregation and Oxygenation. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	17
29	Lack of the Major Multifunctional Catalase KatA in Pseudomonas aeruginosa Accelerates Evolution of Antibiotic Resistance in Ciprofloxacin-Treated Biofilms. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	12
30	Secretory IgA-mediated immune response in saliva and early detection of Pseudomonas aeruginosa in the lower airways of pediatric cystic fibrosis patients. Medical Microbiology and Immunology, 2019, 208, 205-213.	2.6	13
31	Adjunctive dabigatran therapy improves outcome of experimental left-sided Staphylococcus aureus endocarditis. PLoS ONE, 2019, 14, e0215333.	1.1	18
32	Antibiotic therapy as personalized medicine – general considerations and complicating factors. Apmis, 2019, 127, 361-371.	0.9	44
33	Antimicrobial Activity of \hat{l} ±-Peptide/ \hat{l} 2-Peptoid Lysine-Based Peptidomimetics Against Colistin-Resistant Pseudomonas aeruginosa Isolated From Cystic Fibrosis Patients. Frontiers in Microbiology, 2019, 10, 275.	1.5	19
34	P. aeruginosa flow-cell biofilms are enhanced by repeated phage treatments but can be eradicated by phage–ciprofloxacin combination. Pathogens and Disease, 2019, 77, .	0.8	50
35	Optimization of colistin dosing regimen for cystic fibrosis patients with chronic <i>Pseudomonas aeruginosa</i> biofilm lung infections. Pediatric Pulmonology, 2019, 54, 575-580.	1.0	13
36	Editorial comment. Apmis, 2019, 127, 385-385.	0.9	0

#	Article	IF	Citations
37	Formation of Pseudomonas aeruginosa inhibition zone during tobramycin disk diffusion is due to transition from planktonic to biofilm mode of growth. International Journal of Antimicrobial Agents, 2019, 53, 564-573.	1.1	33
38	Hyperbaric oxygen treatment increases killing of aggregating Pseudomonas aeruginosa isolates from cystic fibrosis patients. Journal of Cystic Fibrosis, 2019, 18, 657-664.	0.3	24
39	A systematic review of studies on the faecal microbiota in anorexia nervosa: future research may need to include microbiota from the small intestine. Eating and Weight Disorders, 2018, 23, 399-418.	1.2	33
40	Mechanisms of humoral immune response against Pseudomonas aeruginosa biofilm infection in cystic fibrosis. Journal of Cystic Fibrosis, 2018, 17, 143-152.	0.3	34
41	IgG avidity to Pseudomonas aeruginosa over the course of chronic lung biofilm infection in cystic fibrosis. Journal of Cystic Fibrosis, 2018, 17, 356-359.	0.3	5
42	<i>Pseudomonas aeruginosa</i> biofilm hampers murine central wound healing by suppression of vascular epithelial growth factor. International Wound Journal, 2018, 15, 123-132.	1.3	18
43	Next generation microbiology and cystic fibrosis diagnostics. Current Opinion in Pulmonary Medicine, 2018, 24, 599-605.	1.2	5
44	Adaptation of Pseudomonas aeruginosa to the chronic phenotype by mutations in the algTmucABD operon in isolates from Brazilian cystic fibrosis patients. PLoS ONE, 2018, 13, e0208013.	1.1	24
45	Evolution of Antibiotic Resistance in Biofilm and Planktonic Pseudomonas aeruginosa Populations Exposed to Subinhibitory Levels of Ciprofloxacin. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	97
46	Modelling of ciprofloxacin killing enhanced by hyperbaric oxygen treatment in Pseudomonas aeruginosa PAO1 biofilms. PLoS ONE, 2018, 13, e0198909.	1.1	21
47	Biofilms and host response – helpful or harmful. Apmis, 2017, 125, 320-338.	0.9	118
48	Chronic urinary tract infections in patients with spinal cord lesions – biofilm infection with need for longâ€term antibiotic treatment. Apmis, 2017, 125, 385-391.	0.9	13
49	Diagnosis of biofilm infections in cystic fibrosis patients. Apmis, 2017, 125, 339-343.	0.9	69
50	A short history of microbial biofilms and biofilm infections. Apmis, 2017, 125, 272-275.	0.9	132
51	Mouse Model of Burn Wound and Infection: Thermal (Hot Air) Lesionâ€Induced Immunosuppression. Current Protocols in Mouse Biology, 2017, 7, 77-87.	1.2	17
52	Hyperbaric Oxygen Sensitizes Anoxic Pseudomonas aeruginosa Biofilm to Ciprofloxacin. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	44
53	Chronic Pseudomonas aeruginosa Biofilm Infection Impairs Murine S100A8/A9 and Neutrophil Effector Cytokines $\hat{a} \in \mathbb{C}$ Implications for Delayed Wound Closure?. Pathogens and Disease, 2017, 75, .	0.8	16
54	Secretory IgA response against Pseudomonas aeruginosa in the upper airways and the link with chronic lung infection in cystic fibrosis. Pathogens and Disease, 2017, 75, .	0.8	13

#	Article	IF	CITATIONS
55	Sinus surgery can improve quality of life, lung infections, and lung function in patients with primary ciliary dyskinesia. International Forum of Allergy and Rhinology, 2017, 7, 240-247.	1.5	46
56	Evaluation of a bovine antibody test for diagnosing <i>Mycobacterium avium </i> complex in patients with cystic fibrosis. Pediatric Pulmonology, 2017, 52, 34-40.	1.0	6
57	Immune Modulating Topical S100A8/A9 Inhibits Growth of Pseudomonas aeruginosa and Mitigates Biofilm Infection in Chronic Wounds. International Journal of Molecular Sciences, 2017, 18, 1359.	1.8	13
58	Diffusion Retardation by Binding of Tobramycin in an Alginate Biofilm Model. PLoS ONE, 2016, 11, e0153616.	1.1	40
59	Activation of pulmonary and lymph node dendritic cells during chronic <i>Pseudomonas aeruginosa</i> lung infection in mice. Apmis, 2016, 124, 500-507.	0.9	12
60	Genome Sequence of Pseudomonas aeruginosa Strain DK1-NH57388A, a Stable Mucoid Cystic Fibrosis Isolate. Genome Announcements, 2016, 4, .	0.8	11
61	Comparing the harmful effects of nontuberculous mycobacteria and Gram negative bacteria on lung function in patients with cystic fibrosis. Journal of Cystic Fibrosis, 2016, 15, 380-385.	0.3	111
62	The dlt genes play a role in antimicrobial tolerance of Streptococcus mutans biofilms. International Journal of Antimicrobial Agents, 2016, 48, 298-304.	1,1	45
63	Bacterial evolution in PCD and CF patients follows the same mutational steps. Scientific Reports, 2016, 6, 28732.	1.6	38
64	S100A8/A9 is an important host defence mediator in neuropathic foot ulcers in patients with type 2 diabetes mellitus. Archives of Dermatological Research, 2016, 308, 347-355.	1.1	23
65	Reinforcement of the bactericidal effect of ciprofloxacin on Pseudomonas aeruginosa biofilm by hyperbaric oxygen treatment. International Journal of Antimicrobial Agents, 2016, 47, 163-167.	1.1	68
66	OligoG CF-5/20 Disruption of Mucoid Pseudomonas aeruginosa Biofilm in a Murine Lung Infection Model. Antimicrobial Agents and Chemotherapy, 2016, 60, 2620-2626.	1.4	52
67	Anti- <i>Pseudomonas aeruginosa</i> lgY antibodies promote bacterial opsonization and augment the phagocytic activity of polymorphonuclear neutrophils. Human Vaccines and Immunotherapeutics, 2016, 12, 1-10.	1.4	24
68	Increased bactericidal activity of colistin on <i>Pseudomonas aeruginosa</i> biofilms in anaerobic conditions. Pathogens and Disease, 2016, 74, ftv086.	0.8	34
69	The phenotypic evolution of Pseudomonas aeruginosa populations changes in the presence of subinhibitory concentrations of ciprofloxacin. Microbiology (United Kingdom), 2016, 162, 865-875.	0.7	30
70	The LapG protein plays a role in <i>Pseudomonas aeruginosa</i> biofilm formation by controlling the presence of the CdrA adhesin on the cell surface. MicrobiologyOpen, 2015, 4, 917-930.	1,2	63
71	Autofluorescence in samples obtained from chronic biofilm infections – "all that glitters is not gold― Pathogens and Disease, 2015, 73, .	0.8	13
72	Epidemiology of nontuberculous mycobacteria among patients with cystic fibrosis in Scandinavia. Journal of Cystic Fibrosis, 2015, 14, 46-52.	0.3	107

#	Article	IF	Citations
73	The effect of short-term, high-dose oral N-acetylcysteine treatment on oxidative stress markers in cystic fibrosis patients with chronic P. aeruginosa infection $\hat{a}\in$ A pilot study. Journal of Cystic Fibrosis, 2015, 14, 211-218.	0.3	31
74	Strategies for combating bacterial biofilm infections. International Journal of Oral Science, 2015, 7, 1-7.	3.6	696
75	Identification of outer membrane Porin D as a vitronectin-binding factor in cystic fibrosis clinical isolates of Pseudomonas aeruginosa. Journal of Cystic Fibrosis, 2015, 14, 600-607.	0.3	18
76	Diversity of metabolic profiles of cystic fibrosis Pseudomonas aeruginosa during the early stages of lung infection. Microbiology (United Kingdom), 2015, 161, 1447-1462.	0.7	27
77	Antibiotic penetration and bacterial killing in a <i>Pseudomonas aeruginosa</i> biofilm model. Journal of Antimicrobial Chemotherapy, 2015, 70, 2057-2063.	1.3	50
78	Oropharyngeal Candidiasis in Palliative Care Patients in Denmark. Journal of Palliative Medicine, 2015, 18, 940-944.	0.6	10
79	Chronic pulmonary disease with <i>Mycobacterium abscessus</i> complex is a biofilm infection. European Respiratory Journal, 2015, 46, 1823-1826.	3.1	120
80	Serodiagnosis of i>Mycobacterium abscessus i>complex infection in cystic fibrosis. European Respiratory Journal, 2015, 46, 707-716.	3.1	30
81	Simultaneous sinus and lung infections in patients with primary ciliary dyskinesia. Acta Oto-Laryngologica, 2015, 135, 58-63.	0.3	40
82	Antimicrobial resistance, respiratory tract infections and role of biofilms in lung infections in cystic fibrosis patients. Advanced Drug Delivery Reviews, 2015, 85, 7-23.	6.6	250
83	Antibiofilm Properties of Acetic Acid. Advances in Wound Care, 2015, 4, 363-372.	2.6	118
84	Denitrification by cystic fibrosis pathogens – Stenotrophomonas maltophilia is dormant in sputum. International Journal of Medical Microbiology, 2015, 305, 1-10.	1.5	34
85	Physiological levels of nitrate support anoxic growth by denitrification of Pseudomonas aeruginosa at growth rates reported in cystic fibrosis lungs and sputum. Frontiers in Microbiology, 2014, 5, 554.	1.5	68
86	Urine lipoarabinomannan point-of-care testing in patients affected by pulmonary nontuberculous mycobacteria $\hat{a} \in \text{``experiences}$ from the Danish Cystic Fibrosis cohort study. BMC Infectious Diseases, 2014, 14, 655.	1.3	17
87	A personal history of research on microbial biofilms and biofilm infections. Pathogens and Disease, 2014, 70, 205-211.	0.8	60
88	Bactericidal effect of colistin on planktonic Pseudomonas aeruginosa is independent of hydroxyl radical formation. International Journal of Antimicrobial Agents, 2014, 43, 140-147.	1.1	56
89	Environmental Heterogeneity Drives Within-Host Diversification and Evolution of Pseudomonas aeruginosa. MBio, 2014, 5, e01592-14.	1.8	153
90	Polymorphonuclear Leukocytes Restrict Growth of Pseudomonas aeruginosa in the Lungs of Cystic Fibrosis Patients. Infection and Immunity, 2014, 82, 4477-4486.	1.0	138

#	Article	IF	CITATIONS
91	Staphylococcus aureus Alters Growth Activity, Autolysis, and Antibiotic Tolerance in a Human Host-Adapted Pseudomonas aeruginosa Lineage. Journal of Bacteriology, 2014, 196, 3903-3911.	1.0	68
92	Nitrous Oxide Production in Sputum from Cystic Fibrosis Patients with Chronic Pseudomonas aeruginosa Lung Infection. PLoS ONE, 2014, 9, e84353.	1.1	86
93	Evolution and diversification of <i>Pseudomonas aeruginosa</i> in the paranasal sinuses of cystic fibrosis children have implications for chronic lung infection. ISME Journal, 2012, 6, 31-45.	4.4	184
94	Phenotypes selected during chronic lung infection in cystic fibrosis patients: implications for the treatment of Pseudomonas aeruginosa biofilm infections. FEMS Immunology and Medical Microbiology, 2012, 66, 120-120.	2.7	2
95	The clinical impact of bacterial biofilms. International Journal of Oral Science, 2011, 3, 55-65.	3.6	663
96	Recent advances in the treatment of Pseudomonas aeruginosainfections in cystic fibrosis. BMC Medicine, 2011, 9, 32.	2.3	201
97	Genetic adaptation of Pseudomonas aeruginosa during chronic lung infection of patients with cystic fibrosis: strong and weak mutators with heterogeneous genetic backgrounds emerge in mucA and/or lasR mutants. Microbiology (United Kingdom), 2010, 156, 1108-1119.	0.7	171
98	<i>Pseudomonas aeruginosa</i> biofilms in cystic fibrosis. Future Microbiology, 2010, 5, 1663-1674.	1.0	557
99	Antibiotic resistance of bacterial biofilms. International Journal of Antimicrobial Agents, 2010, 35, 322-332.	1.1	2,809
100	Pseudomonas aeruginosa recognizes and responds aggressively to the presence of polymorphonuclear leukocytes. Microbiology (United Kingdom), 2009, 155, 3500-3508.	0.7	207
101	THE SEROLOGY OF PSEUDOMONAS AERUGINOSA ANALYSED BY MEANS OF QUANTITATIVE IMMUNOELECTROPHORETIC METHODS. Acta Pathologica Microbiologica Scandinavica Section B Microbiology, 2009, 83B, 321-327.	0.0	1
102	THE SEROLOGY OF PSEUDOMONAS AERUGINOSA ANALYSED BY MEANS OF QUANTITATIVE IMMUNOELECTROPHORETIC METHODS. Acta Pathologica Microbiologica Scandinavica Section B Microbiology, 2009, 83B, 328-334.	0.0	0
103	THE SEROLOGY OF PSEUDOMONAS AERUGINOSA ANALYSED BY MEANS OF QUANTITATIVE IMMUNOELECTROPHORETIC METHODS. Acta Pathologica Microbiologica Scandinavica Section B Microbiology, 2009, 83B, 433-442.	0.0	0
104	THE SEROLOGY OF PSEUDOMON AS AERUGINOSA ANALYSED BY MEANS OF QUANTITATIVE IMMUNOELECTROPHORETIC METHODS. Acta Pathologica Et Microbiologica Scandinavica Section C, Immunology, 2009, 84C, 372-382.	0.0	4
105	THE SEROLOGY OF PSEUDOMONAS AERUGINOSA ANALYSED BY MEANS OF QUANTITATIVE IMMUNOELECTROPHORETIC METHODS. Acta Pathologica Et Microbiologica Scandinavica Section C, Immunology, 2009, 84C, 383-389.	0.0	1
106	Investigation of the algT operon sequence in mucoid and non-mucoid Pseudomonas aeruginosa isolates from 115 Scandinavian patients with cystic fibrosis and in 88 in vitro non-mucoid revertants. Microbiology (United Kingdom), 2008, 154, 103-113.	0.7	77
107	Impact of Pseudomonas aeruginosa quorum sensing on biofilm persistence in an in vivo intraperitoneal foreign-body infection model. Microbiology (United Kingdom), 2007, 153, 2312-2320.	0.7	124
108	Rapid necrotic killing of polymorphonuclear leukocytes is caused by quorum-sensing-controlled production of rhamnolipid by Pseudomonas aeruginosa. Microbiology (United Kingdom), 2007, 153, 1329-1338.	0.7	362

#	Article	IF	CITATIONS
109	Occurrence of Hypermutable Pseudomonas aeruginosa in Cystic Fibrosis Patients Is Associated with the Oxidative Stress Caused by Chronic Lung Inflammation. Antimicrobial Agents and Chemotherapy, 2005, 49, 2276-2282.	1.4	232
110	The MexGHI-OpmD multidrug efflux pump controls growth, antibiotic susceptibility and virulence in Pseudomonas aeruginosa via 4-quinolone-dependent cell-to-cell communication. Microbiology (United Kingdom), 2005, 151, 1113-1125.	0.7	204
111	Garlic blocks quorum sensing and promotes rapid clearing of pulmonary Pseudomonas aeruginosa infections. Microbiology (United Kingdom), 2005, 151, 3873-3880.	0.7	381
112	Pseudomonas aeruginosa tolerance to tobramycin, hydrogen peroxide and polymorphonuclear leukocytes is quorum-sensing dependent. Microbiology (United Kingdom), 2005, 151, 373-383.	0.7	451
113	Pseudomonas aeruginosa alginate is refractory to Th1 immune response and impedes host immune clearance in a mouse model of acute lung infection. Journal of Medical Microbiology, 2003, 52, 731-740.	0.7	76
114	New antimicrobials in the management of cystic fibrosis. Journal of Antimicrobial Chemotherapy, 2002, 49, 235-238.	1.3	40
115	Inhibition of quorum sensing in Pseudomonas aeruginosa biofilm bacteria by a halogenated furanone compound. Microbiology (United Kingdom), 2002, 148, 87-102.	0.7	919
116	Understanding bacterial biofilms in patients with cystic fibrosis: current and innovative approaches to potential therapies. Journal of Cystic Fibrosis, 2002, 1, 249-254.	0.3	109
117	Urinary Tract Infections in Patients with Spinal Cord Lesions. Drugs, 2001, 61, 1275-1287.	4.9	97
118	Pseudomonas aeruginosa mutations in lasI and rhll quorum sensing systems result in milder chronic lung infection. Microbiology (United Kingdom), 2001, 147, 1105-1113.	0.7	177
119	Pseudomonas aeruginosa cross-infection among patients with cystic fibrosis during a winter camp. , 2000, 29, 177-181.		92
120	Rapid development in vitro and in vivo of resistance to ceftazidime in biofilm-growing Pseudomonas aeruginosa due to chromosomal AE-lactamaseNote. Apmis, 2000, 108, 589-600.	0.9	55
121	The immune response to chronic Pseudomonas aeruginosa lung infection in cystic fibrosis patients is predominantly of the Th2 typeNote. Apmis, 2000, 108, 329-335.	0.9	155
122	Production of N-acyl-L-homoserine lactones by P. aeruginosaisolates from chronic lung infections associated with cystic fibrosis. FEMS Microbiology Letters, 2000, 184, 273-278.	0.7	73
123	Detection of N-acylhomoserine lactones in lung tissues of mice infected with Pseudomonas aeruginosa. Microbiology (United Kingdom), 2000, 146, 2481-2493.	0.7	156
124	Prospects for the Prevention and Control of Pseudomonal Infection in Children with Cystic Fibrosis. Paediatric Drugs, 2000, 2, 451-463.	1.3	40
125	Pseudomonas aeruginosa cross-infection among patients with cystic fibrosis during a winter camp., 2000, 29, 177.		1
126	Results of Multiple Diagnostic Tests for <i>Mycobacterium avium</i> subsp. <i>paratuberculosis</i> in Patients with Inflammatory Bowel Disease and in Controls. Journal of Clinical Microbiology, 2000, 38, 4373-4381.	1.8	125

#	Article	IF	CITATIONS
127	Early immune response in susceptible and resistant mice strains with chronic <i>Pseudomonas aeruginosa</i> lung infection determines the type of Tâ€helper cell response. Apmis, 1999, 107, 1093-1100.	0.9	63
128	Mucoid conversion of Pseudomonas aeruginos by hydrogen peroxide: a mechanism for virulence activation in the cystic fibrosis lung. Microbiology (United Kingdom), 1999, 145, 1349-1357.	0.7	437
129	Ulcer bed infection. Apmis, 1998, 106, 721-726.	0.9	24
130	Serological diagnosis of experimental <i>Enterococcus faecalis</i> endocarditis. Apmis, 1998, 106, 997-1008.	0.9	6
131	Pseudomonas aeruginosa andBurkholderia cepacia infection in cystic fibrosis patients treated in Toronto and Copenhagen. , 1998, 26, 89-96.		43
132	<i>Ginseng</i> treatment enhances bacterial clearance and decreases lung pathology in athymic rats with chronic <i>P. aeruginosa</i> pneumonia. Apmis, 1997, 105, 438-444.	0.9	45
133	Chronic <i>Pseudomonas aeruginosa</i> lung infection is more severe in Th ₂ responding BALB/c mice compared to Th ₁ responding C ₃ H/HeN mice. Apmis, 1997, 105, 838-842.	0.9	110
134	Effects of Chinese medicinal herbs on a rat model of chronicPseudomonas aeruginosalung infection. Apmis, 1996, 104, 350-354.	0.9	14
135	Cloning and nucleotide sequence comparison of the <i>groE</i> operon of <i>Pseudomonas aeruginosa</i> and <i>Burkholderia cepacia</i> Apmis, 1995, 103, 113-123.	0.9	9
136	Experimental chronic <i>Pseudomonas aeruginosa</i> lung infection in rats. Apmis, 1995, 103, 367-374.	0.9	7
137	The Legionella micdadei flagellin: Expression in Escherichia coli K 12 and DNA sequence of the gene. Apmis, 1995, 103, 869-877.	0.9	8
138	High levels of complement-activation capacity in sera from patients with cystic fibrosis correlate with high levels of IgG3 antibodies toPseudomonas aeruginosa antigens and poor lung function. Pediatric Pulmonology, 1995, 20, 71-77.	1.0	12
139	Antigenic analysis of Pseudomonas aeruginosa and Pseudomonas cepacia GroEL proteins and demonstration of a lipopolysaccharide-associated GroEL fraction in P. aeruginosa. Apmis, 1993, 101, 621-630.	0.9	11
140	IgG subclass antibody responses to alginate fromPseudomonas aeruginosa in patients with cystic fibrosis and chronicP. aeruginosa infection. Pediatric Pulmonology, 1992, 14, 44-51.	1.0	27
141	Local IgA and IgG response to intratracheal immunization with <i>Pseudomonas aeruginosa</i> antigens. Apmis, 1992, 100, 87-90.	0.9	14
142	Lipopolysaccharide is present in immune complexes isolated from sputum in patients with cystic fibrosis and chronic <i>Pseudomonas aeruginosa</i> lung infection. Apmis, 1992, 100, 175-180.	0.9	22
143	Some bacterial parameters influencing the neutrophil oxidative burst response to <i>Pseudomonas aeruginosa</i> biofilms. Apmis, 1992, 100, 727-733.	0.9	46
144	Experimental studies of survival of anaerobic bacteria at 4°C and 22°C in two different transport systems. Apmis, 1992, 100, 1048-1052.	0.9	5

#	Article	IF	Citations
145	Relationship Between Chemical Composition and Biological Function of $\langle i \rangle$ Pseudomonas aeruginosa $\langle i \rangle$ Lipopolysaccharide: Effect on Human Neutrophil Chemotaxis and Oxidative Burst. Journal of Leukocyte Biology, 1991, 49, 15-20.	1.5	23
146	Experimental immunization with <i>Pseudomonas aeruginosa</i> alginate induces IgA and IgG antibody responses. Apmis, 1991, 99, 1061-1068.	0.9	18
147	Retrospective Clinical Study of Hypersensitivity Reactions to Aztreonam and Six Other \hat{l}^2 -Lactam Antibiotics in Cystic Fibrosis Patients Receiving Multiple Treatment Courses. Clinical Infectious Diseases, 1991, 13, S608-S611.	2.9	68
148	Adhesion of <i>Yersinia enterocolitica</i> to human epithelial cell lines and to rabbit and human small intestinal tissue. Apmis, 1990, 98, 53-60.	0.9	10
149	Crossed immunoelectrophoretic analysis of Flavobacterium meningosepticum DNA hybridization groups I and II. Apmis, 1989, 97, 591-594.	0.9	1
150	Crossed immunoâ€electrophoretic analysis of <i>Yersinia enterocolitica</i> serotype 0:3 antigens. Apmis, 1988, 96, 306-314.	0.9	3
151	Comparison of Amoxycillin/Clavulanate with Amoxycillin in Children and Adults with Chronic Obstructive Pulmonary Disease and Infection with Haemophilus influenzae. Scandinavian Journal of Infectious Diseases, 1988, 20, 517-524.	1.5	7
152	Strict Protective Isolation in Allogeneic Bone Marrow Transplantation: Effect on Infectious Complications, Fever and Graft Versus Host Disease. Scandinavian Journal of Infectious Diseases, 1987, 19, 91-96.	1.5	27
153	A Comparative Study of Amoxycillin and Pivampicillin in Persistent Haemophilus influenzae Infection of the Lower Respiratory Tract in Children with Chronic Lung Disease. Scandinavian Journal of Infectious Diseases, 1986, 18, 245-254.	1.5	5
154	Pseudomonas cepacia Septicemia in Patients with Burns: Report of Two Cases. Scandinavian Journal of Infectious Diseases, 1985, 17, 63-66.	1.5	9
155	Polyagglutinability Due to Loss of Oâ€Antigenic Determinants in <i>Pseudomonas Aeruginosa</i> Strains Isolated from Cystic Fibrosis Patients. Acta Pathologica, Microbiologica, Et Immunologica Scandinavica Section B, Microbiology, 1985, 93B, 7-13.	0.1	26
156	IMMUNOLOGICAL CROSSâ€REACTION BETWEEN ANTIGEN Tpâ€4 OF <i>TREPONEMA PALLIDUM</i> AND AN ANTIGEN COMMON TO A WIDE RANGE OF BACTERIA. Acta Pathologica, Microbiologica, Et Immunologica Scandinavica Section B, Microbiology, 1984, 92B, 183-188.	0.1	27
157	Microbiological and Immunological Studies in a Case of Human Melioidosis Diagnosed in Denmark. Scandinavian Journal of Infectious Diseases, 1982, 14, 271-275.	1.5	29
158	IMMUNE COMPLEX MEDIATED TISSUE DAMAGE IN THE LUNGS OF CYSTIC FIBROSIS PATIENTS WITH CHRONIC PSEUDOMONAS AERUGINOSA INFECTION. Acta Paediatrica, International Journal of Paediatrics, 1982, 71, 63-73.	0.7	31
159	MICROBIOLOGY OF LUNG INFECTIONS IN CYSTIC FIBROSIS PATIENTS. Acta Paediatrica, International Journal of Paediatrics, 1982, 71, 33-54.	0.7	196
160	ANTIMICROBIAL CHEMOTHERAPY IN CYSTIC FIBROSIS PATIENTS. Acta Paediatrica, International Journal of Paediatrics, 1982, 71, 75-100.	0.7	75
161	Studies on Hypersensitivity to Bacterial Antigens in Intrinsic Asthma. Allergy: European Journal of Allergy and Clinical Immunology, 1982, 37, 191-201.	2.7	26
162	QUANTITATIVE STUDIES ON IMMUNOLOGICALLY SPECIFIC AND NONâ€SPECIFIC ABSORPTION OF ⟨i⟩PSEUDOMONAS AERUGINOSA⟨ i⟩ ANTIBODIES IN SERUM FROM CYSTIC FIBROSIS PATIENTS. Acta Pathologica Et Microbiologica Scandinavica Section C, Immunology, 1981, 89C, 185-192.	0.0	1

#	Article	IF	CITATIONS
163	EPIDEMIOLOGY OF <i>PSEUDOMONAS AERUGINOSA</i> INFECTION IN PATIENTS TREATED AT A CYSTIC FIBROSIS CENTRE. Acta Pathologica Microbiologica Scandinavica Section B Microbiology, 1980, 88B, 125-131.	0.0	46
164	PRECIPITATING ANTIBODIES AGAINSTESCHERICHIA COLI, BACTEROIDES FRAGILIS SS. THETAIOTAOMICRONANDPSEUDOMONAS AERUGINOSAIN SERUM FROM NORMAL PERSONS AND CYSTIC FIBROSIS PATIENTS, DETERMINED BY MEANS OF CROSSED IMMUNOELECTROPHORESIS. Acta Paediatrica, International Journal of Paediatrics, 1979, 68, 495-500.	0.7	11
165	HYPERGAMMAGLOBULINEMIC PURPURA IN CYSTIC FIBROSIS. Acta Paediatrica, International Journal of Paediatrics, 1978, 67, 443-447.	0.7	24
166	CROSSED IMMUNOELECTROPHORETIC ANALYSIS OF <i>NEISSERIA MENINGITIDIS</i> ANTIGENS AND OF CORRESPONDING ANTIBODIES IN PATIENTS WITH MENINGOCOCCAL DISEASE. Acta Pathologica Et Microbiologica Scandinavica Section C, Immunology, 1978, 86C, 1-9.	0.0	5
167	IMMUNE COMPLEXES IN CYSTIC FIBROSIS. Acta Pathologica Et Microbiologica Scandinavica Section C, Immunology, 1977, 85C, 57-64.	0.0	17
168	PSEUDOMONAS AERUGINOSA INFECTION IN CYSTIC FIBROSIS:. Acta Pathologica Et Microbiologica Scandinavica Section C, Immunology, 1977, 85C, 107-114.	0.0	20
169	ANTIBODIES AGAINST PSEUDOMONAS AERUGINOSA IN SERUM FROM NORMAL PERSONS AND PATIENTS COLONIZED WITH MUCOID OR NONâ€MUCOID PSEUDOMONAS AERUGINOSA: RESULTS OBTAINED BY CROSSED IMMUNOELECTROPHORESIS. Acta Pathologica Et Microbiologica Scandinavica Section C, Immunology, 1977, 85C, 142-148.	0.0	4
170	PSEUDOMONAS AERUGINOSA INFECTION IN CYSTIC FIBROSIS:. Acta Pathologica Et Microbiologica Scandinavica Section C, Immunology, 1977, 85C, 149-152.	0.0	1
171	CROSSâ€REACTIONS BETWEEN <i>BORDETELLA PERTUSSIS</i> AND TWENTYâ€EIGHT OTHER BACTERIAL SPECIE Acta Pathologica Microbiologica Scandinavica Section B Microbiology, 1976, 84B, 395-400.	.S 0.0	15
172	<i>STAPHYLOCOCCUS AUREUS</i> IN CYSTIC FIBROSIS: ANTIBIOTIC SENSITIVITY AND PHAGE TYPES DURING THE LATEST DECADE. Acta Pathologica Microbiologica Scandinavica Section B Microbiology, 1975, 83B, 219-225.	0.0	3
173	EPIDEMIOLOGICAL MARKERS FOR <i>PSEUDOMONAS AERUGINOSA</i> Scandinavica Section B Microbiology, 1975, 83B, 553-560.	0.0	0
174	NITROBLUEâ€TETRAZOLIUM (NBT)â€REDUCTION BY HUMAN PERIPHERAL NEUTROPHIL GRANULOCYTES IN THE PRESENCE OF BACTERIAL ANTIGENS. Acta Pathologica Et Microbiologica Scandinavica Section C, Immunology, 1975, 83C, 144-156.	0.0	0
175	PSEUDOMONAS AERUGINOSA INFECTION IN CYSTIC FIBROSIS: Occurrence of Precipitating Antibodies against Pseudomonas Aeruginosa in Relation to the Concentration of Sixteen Serum Proteins and the Clinical and Radiographical Status of thi Lungs. Acta Paediatrica, International Journal of Paediatrics, 1974. 63. 843-848.	0.7	22
176	EPIDEMIOLOGICAL INVESTIGATIONS OF THE RESPIRATORY TRACT BACTERIOLOGY IN PATIENTS WITH CYSTIC FIBROSIS. Acta Pathologica Et Microbiologica Scandinavica - Section B Microbiology and Immunology, 1974, 82B, 541-550.	0.0	27
177	<i>PSEUDOMONAS AERUGINOSA</i> INFECTION IN CYSTIC FIBROSIS. <i>Relationship between mucoid strains of</i> Pseudomonas aeruginosa <i> and the humoral immune response</i> Acta Pathologica Et Microbiologica Scandinavica - Section B Microbiology and Immunology, 1974, 82B, 551-558.	0.0	37
178	<i>PSEUDOMONAS AERUGINOSA</i> INFECTION IN CYSTIC FIBROSIS Acta Pathologica Et Microbiologica Scandinavica - Section B Microbiology and Immunology, 1974, 82B, 559-566.	0.0	1
179	IDENTIFICATION AND QUANTITATION OF PRECIPITINS AGAINST <i>PSEUDOMONAS AERUGINOSA</i> IN PATIENTS WITH CYSTIC FIBROSIS BY MEANS OF CROSSED IMMUNOELECTROPHORESIS WITH INTERMEDIATE GEL. Acta Pathologica Et Microbiologica Scandinavica - Section B Microbiology and Immunology, 1973, 81B. 298-308.	0.0	49